🔗 Share this article

Given that America undertakes sweeping adjustments to its vaccine guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccines throughout the global health crisis and has focused upon alleged deaths following COVID-19 vaccination in her brief tenure at the FDA.

Scheduled Shifts to Pediatric Immunization Schedule

Agency leaders had intended to announce major changes to the childhood immunization program recently, synchronizing the US with Denmark’s vaccine program, it is understood – a major change that would place the US out of step with many the global community with little proof for improved outcomes. The planned update has been delayed until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to speak at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Høeg has often pushed for discontinuing specific pediatric vaccine recommendations in the US so as to align more like the Danish model, a country with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

To date public appearances, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Qualifications

Høeg has little discernible track record in pharmaceutical research, regulation or administrative roles, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since spring.

“She appears not to have the necessary background” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She has no expertise in leading a major agency. She has no expertise in industry regulation.”

Former directors of CBER would “be deeply familiar with laws and regulations and the science of medication creation”, said Janet Woodcock. “Objectively, she has not acquired the kind of background that prior appointees who headed the center have had.”

The drug center has an enormous workload at the FDA, the former commissioner emphasized.

“Everybody just pays attention on the new drug program, but the generic program authorizes numerous generic medications. There is also a biologic copycat branch, over-the-counter program and so forth, and each of these have to be looked after,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Additionally, a major management component to the role, which supervises more than 5,000 employees. “It’s a massive leadership role, if you execute it properly,” Woodcock said.

Response and Disputed Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this assignment signifies increased cooperation among agency officials on immunizations, a spokesperson stated that the “inquiries rely on flawed assumptions”.

“Her experience aligns with the responsibilities of her job,” the representative explained, pointing to the time Dr. Høeg spent advising the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s new expedited review system, a disputed expedited therapy clearance system that reportedly troubled her former heads. “By what process are these drugs being selected for this fast-track system? Who makes the choices?” Howard said. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards more relaxed rules of pharmaceuticals, except for vaccines.”

Public Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if problematic, past, some experts said. She released a study using unconfirmed crowd-sourced reports to estimate the rate of heart inflammation after COVID-19 immunization. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming federal leadership featured revising regulations for new vaccines and halting “non-essential” vaccines, she stated after the election on a audio program. At the FDA, Høeg has according to sources proposed preventing teenage boys from receiving Covid vaccines.

“She is an all-around dogmatist who begins with her conclusions and tailors the evidence to retrofit the evidence in a extremely deceptive, untruthful way,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|